A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
National Institutes of Health Clinical Center (CC)
Herlev Hospital
Vejle Hospital
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Vejle Hospital
Peking University
Rigshospitalet, Denmark